Loading...
Please wait, while we are loading the content...
Similar Documents
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
| Content Provider | Scilit |
|---|---|
| Author | Isaacsohn, Jonathan Hunninghake, Donald Schrott, Helmut Dujovne, Carlos A. Knopp, Robert Weiss, Stuart R. Bays, Harold Crousei, John R. Davidson, Michael H. Keilson, Leonard M. McKenney, James Korenman, Stanley G. Dobs, Adrian S. Stein, Evan Krauss, Ronald M. Maccubbin, Darbie Cho, Meeh Yung Plotkin, Diane J. Mitchel, Yale B. |
| Copyright Year | 2003 |
| Description | Journal: Clinical Cardiology Background: Patients with elevated levels of serum triglyc‐erides (TG) often have other associated lipid abnormalities (e.g., low levels of high‐density lipoprotein cholesterol [HDL‐C]) and are at increased risk of developing coronary heart disease. Although the therapeutic benefits of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) in hypercholesterolemic patients have been well established, less is known about the effects of statins in patient populations with hypertriglyceridemia. Hypothesis: The purpose of this study was to evaluate the lipoprotein‐altering efficacy of simvastatin in hypertriglyceri‐demic patients. Methods: This was a multicenter, randomized, double‐blind, placebo‐controlled study. In all, 195 patients with fasting serum triglyceride levels between 300 and 900 mg/dl received once daily doses of placebo or simvastatin 20,40, or 80 mg for 6 weeks. Results: Compared with placebo, simvastatin treatment across all doses resulted in significant reductions (p < 0.05–<0.001) in serum levels of triglycerides (‐20 to–31% decrease) and TG‐rich lipoprotein particles. Significant (p< 0.001) reductions were also seen in low‐density lipoprotein cholesterol (‐25 to‐35%)andnon‐HDL‐C(‐26to‐40%). Levels of HDL‐C were increased (7‐11%) in the simvastatin groups compared with placebo (p < 0.05‐ < 0.001). Conclusion: The results of this study demonstrate the beneficial effects of simvastatin in patients with hypertriglyceridemia. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6654219/pdf |
| Ending Page | 24 |
| Page Count | 7 |
| Starting Page | 18 |
| e-ISSN | 19328737 |
| DOI | 10.1002/clc.4960260105 |
| Journal | Clinical Cardiology |
| Issue Number | 1 |
| Volume Number | 26 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2003-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Clinical Cardiology Medical Laboratory Technology Hypertriglyceridemia 3‐hydroxy‐3‐methylglutaryl Coenzyme A Reductase Inhibitors, Lipoprotein |
| Content Type | Text |
| Resource Type | Article |
